Clinical trials: Estrogen Therapy
Cardiac Affections
Comparison of Cardiotoxicity Induced by Selective Estrogen REceptor Modulators and aNti-Aromatase
Selective estrogen receptor modulators and aromatase inhibitors for the treatment of breast cancer seems to have an impact on the cardio-vascular system.
- Trial name
- SERENA (NCT03259711)
- Testing
- Hormonal therapies L02 in the ATC classification
- Where
- France
- Volunteers
- 20,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Locally Advanced or Metastatic Breast Cancer
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human…
- Trial name
- NCT05296798
- Testing
- Phesgo, Giredestrant, Docetaxel
- Where
- 198 sites in United States, Argentina and 27 more
- Volunteers
- 922 people
- Sponsor
- Hoffmann-La Roche
Menopause, Premature, Hysterectomy
Perception and Attitude Toward Estrogen Therapy Among Surgically Menopausal Women
The aim of this study is to survey patient's cognition and attitude about health-related quality of life, use of estrogen, experience of menopausal syndrome, compliance of medication, experience, and satisfaction for women who…
- Conditions
- Menopause, Premature, Hysterectomy, Ovariectomy, Estrogen Replacement Therapy
- Trial name
- NCT00173550
- Testing
- Hysterectomy and Bilateral salpingo-oophorectomy
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Advanced or Metastatic Breast Cancer
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer.
- Trial name
- NCT06105632
- Testing
- PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus
- Where
- 48 sites in United States, Argentina and 12 more
- Volunteers
- 333 people
- Sponsor
- Pfizer
Traumatic Brain Injury
Resuscitative Endocrinology:Single-dose Clinical Uses for Estrogen-Traumatic Brain Injury
Each year in the United States alone, a third of a million persons are hospitalized for traumatic brain injury (TBI), of whom approximately 1/4 die. Most are less than 30 years of age.
- Trial name
- RESCUE-TBI (NCT00973674)
- Testing
- Premarin IV
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
This was an open label, multi-center protocol for U.S. patients enrolled in the study of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast…
- Trial name
- EarLEE-1 (NCT03078751)
- Testing
- Ribociclib, Adjuvant endocrine therapy
- Where
- 33 sites in United States
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy
RATIONALE: High doses of esterified estrogens may stop the growth of breast cancer cells that no longer respond to hormone therapy.
- Trial name
- NCT00131924
- Testing
- esterified estrogens
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Sleep Disorders
Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep Disturbances
The purpose of this study is to examine the effects of giving growth hormone releasing hormone (GHRH) to treat sleep disorders in older men and in older women who are on estrogen replacement therapy (ERT).
- Trial name
- NCT00000380
- Testing
- GHRH
- Sponsor
- University of Washington
Breast Neoplasms
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast…
- Trial name
- NCT01740427
- Testing
- PD-0332991, Letrozole
- Where
- 305 sites in United States, Australia and 16 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
To Determine Whether Estrogen Influences the Effects of Training on Glycemic Control and Insulin Sensitivity
Does Estrogen Blunt the Effects of Exercise Training on Glycemic Control
Previous research has found that males and females respond differently to exercise training, particularly with respect to improvements in blood sugar control and immune system health.
- Trial name
- NCT07791394
- Testing
- EXERCISE TRAINING WITH OR WITHOUT MEDICATION
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Waterloo
Endometrial Hyperplasia, Endometrial Cancer
Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen
The objective of the study is to confirm that the efficacy of vaginal progesterone is at least as good as oral progesterone in order to protect the endometrium of uncontrolled proliferation and prevent endometrial cancer.
- Trial name
- NCT00919919
- Testing
- progesterone, activella
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center
Breast Cancer
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk…
- Trial name
- CheckMate 7FL (NCT04109066)
- Testing
- nivolumab, paclitaxel (PTX), anthracycline
- Where
- 240 sites in United States, Argentina and 30 more
- Volunteers
- 521 people
- Sponsor
- Bristol-Myers Squibb
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
This phase Ib trials studies the side effects and how well talimogene laherparepvec works when given together with chemotherapy or endocrine therapy in treating patients with breast cancer that does not express the human…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT03554044
- Testing
- Anastrozole, Exemestane, Fulvestrant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Unspecified Injury of Brachial Artery, Left Side, Initial Encounter
Vascular Effect of Estrogens Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery
The aim of this study is to evaluate the vascular effects of estrogens on climacteric women measured by flow-mediated evaluation of the brachial artery using high resolution ultrasound and compare to placebo.
- Trial name
- EDILA (NCT01482416)
- Testing
- Estrogens, Conjugated (USP)
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Breast Cancer, Breast Carcinoma
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
This study will look at effects the combination of palbociclib and letrozole may have on estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer tumors which have not yet been…
- Conditions
- Breast Cancer, Breast Carcinoma, Breast Tumors
- Trial name
- PALLET (NCT02296801)
- Testing
- Letrozole, palbociclib
- Where
- 52 sites in United States, Canada and 1 more
- Volunteers
- 307 people
- Sponsor
- NSABP Foundation Inc
Ovarian Cancer
A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
This multicenter, open-label, prospective cohort clinical study enrolled 70 patients with late-stage ER（+）platinum-sensitive recurrent ovarian cancer who had achieved CR/PR after first-line PARP inhibitor maintenance therapy.
- Trial name
- NCT07000344
- Testing
- Cohort 1 (triple-drug group), Cohort 2 (dual-drug group)
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Peking Union Medical College Hospital
Adenomyosis, Chronic Pelvic Pain
Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS)
Adenomyosis is characterized by the appearance of endometrial cells in the muscular layer of the uterus. It affects about 15-20% of the female population.
- Trial name
- NCT02556411
- Testing
- LNG-IUS 13,5 mg Levonorgestrel, Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Cagliari
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
RATIONALE: Studying how older women make treatment decisions and how these decisions affect the outcome of treatment may help doctors plan more effective treatments and improve patient quality of life.
- Trial name
- NCT00068328
- Testing
- psychosocial assessment and care, quality-of-life assessment
- Where
- 85 sites in United States
- Volunteers
- 1,706 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Female Breast Cancer
Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer
The purpose of this study is to evaluate the role of patients' response expectations for nocebo side effects, quality of life and adherence during adjuvant endocrine treatment (AET).
- Trial name
- NCT02088710
- Testing
- Enhanced information about endocrine therapy
- Where
- Germany
- Volunteers
- 138 people
- Sponsor
- Philipps University Marburg
Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
This phase II clinical trial studies how well fulvestrant and palbociclib works in treating older patients with breast cancer that responds to hormone treatment (hormone responsive) that cannot be removed by surgery.
- Conditions
- Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT02760030
- Testing
- Fulvestrant, Laboratory Biomarker Analysis, Palbociclib
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Ohio State University Comprehensive Cancer Center